Location via proxy:   [ UP ]  
[Report a bug]   [Manage cookies]                
Scribd Logo
Upload

Welcome to Scribd!

  • 34 views

    ES - Gliclazide

    Uploaded by

    Kim Ruiz
    Gliclazide is an oral hypoglycemic drug used to treat type 2 diabetes. It works by binding to receptors on pancreatic beta cells, blocking potassium channels and stimulating the release of insulin. It is well absorbed orally but exhibits inter-individual variability, extensively metabolized in the liver, and primarily eliminated through urine and feces. Gliclazide may have increased effects when taken with other antidiabetic drugs, beta-blockers, ACE inhibitors, and NSAIDs, while its effect may be reduced with danazol.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd

    ES - Gliclazide

    Uploaded by

    Kim Ruiz
    34 views1 page
    Gliclazide is an oral hypoglycemic drug used to treat type 2 diabetes. It works by binding to receptors on pancreatic beta cells, blocking potassium channels and stimulating the release of insulin. It is well absorbed orally but exhibits inter-individual variability, extensively metabolized in the liver, and primarily eliminated through urine and feces. Gliclazide may have increased effects when taken with other antidiabetic drugs, beta-blockers, ACE inhibitors, and NSAIDs, while its effect may be reduced with danazol.

    Original Description:

    Pharmacology drug

    Original Title

    ES-_Gliclazide

    Copyright

    © © All Rights Reserved

    Available Formats

    DOCX, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Gliclazide is an oral hypoglycemic drug used to treat type 2 diabetes. It works by binding to receptors on pancreatic beta cells, blocking potassium channels and stimulating the release of insulin. It is well absorbed orally but exhibits inter-individual variability, extensively metabolized in the liver, and primarily eliminated through urine and feces. Gliclazide may have increased effects when taken with other antidiabetic drugs, beta-blockers, ACE inhibitors, and NSAIDs, while its effect may be reduced with danazol.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    34 views1 page

    ES - Gliclazide

    Uploaded by

    Kim Ruiz
    Gliclazide is an oral hypoglycemic drug used to treat type 2 diabetes. It works by binding to receptors on pancreatic beta cells, blocking potassium channels and stimulating the release of insulin. It is well absorbed orally but exhibits inter-individual variability, extensively metabolized in the liver, and primarily eliminated through urine and feces. Gliclazide may have increased effects when taken with other antidiabetic drugs, beta-blockers, ACE inhibitors, and NSAIDs, while its effect may be reduced with danazol.

    Copyright:

    © All Rights Reserved
    Download as DOCX, PDF, TXT or read online from Scribd
    Download as docx, pdf, or txt
    of 1

    Gliclazide

    GENERAL DRUG CLASSIFICATION: CNS-Neurogenerative disease drugs-Cholinesterase inhibitor


    CHEMICAL NAME: 1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea
    [1]

    GENERIC NAME: Gliclazide[1]


    BRAND NAME: Azukon MR [2]
    INDICATIONS: For the treatment of NIDDM in conjunction with diet and exercise. (2)
    PHARMACOKINETICS: Absorption: Rapidly and well absorbed but may have wide inter-
    and intra-individual variability. Peak plasma concentrations occur
    within 4-6 hours of oral administration. [1]

    Distribution: plasma protein binding approximately 94-95 %. [2]

    Metabolism: Extensively metabolized in the liver. Less than 1% of the


    orally administered dose appears unchanged in the urine. Metabolites
    include oxidized and hydroxylated derivates, as well as glucuronic acid
    conjugates. [1]

    Excretion: Metabolites and conjugates are eliminated primarily by the


    kidneys (60-70%) and also in the feces (10-20%).[1]
    PHARMACODYNAMICS: Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding
    subsequently blocks the ATP sensitive potassium channels. The binding
    results in closure of the channels and leads to a resulting decrease in
    potassium efflux leads to depolarization of the β cells. This opens
    voltage-dependent calcium channels in the β cell resulting in calmodulin
    activation, which in turn leads to exocytosis of insulin containing
    secretorty granules. [1]
    DRUG INTERACTIONS: May increase hypoglycaemic effect w/ phenylbutazone. [2]

    Potentiation of blood glucose lowering effect w/ other antidiabetics


    (e.g. acarbose, insulins, metformin), β-blockers, ACE inhibitors, H 2-
    receptor antagonists, MAOIs, sulfonamides, clarithromycin and
    NSAIDs. [2]

    Chlorpromazine, glucocorticoids, ritodrine, salbutamol may cause


    increases in blood glucose levels. [2]

    Terbutaline may cause increases in blood glucose levels. [2]

    May diminish hypoglycaemic effect w/ danazol. May increase


    anticoagulant effect of warfarin. [2]
    LABORATORY INTERFERENCES: No data available
    [1]
    REFERENCES: Gliclazide - DrugBank. Drugbank.ca.
    https://www.drugbank.ca/drugs/DB01120. Published 2018. Accessed
    November 24, 2018.
    [2]
    Gliclazide: Indication, Dosage, Side Effect, Precaution | MIMS.com
    Philippines. Mims.com.
    https://www.mims.com/philippines/drug/info/gliclazide?mtype=generic.
    Published 2018. Accessed 2018.

    You might also like